Evidence map›Paper›PMID 27349588›Full record

ReviewHerz2017

[Aftercare of patients after MitraClip® implantation].

A Schlitt, E Lubos, M Guha, C Hegeler-Molkewehrum, M Sudau, H Schmidt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

A SchlittParacelsus-Harz-Klinik Bad Suderode, Paracelsusstr. 1, 06485, Quedlinburg, Deutschland. prof.dr.axel.schlitt@paracelsus-kliniken.de.
E LubosKlinik für Allgemeine und Interventionelle Kardiologie, Universitäres Herzzentrum Hamburg, Hamburg, Deutschland.
M GuhaReha-Klinik am Sendesaal, Bremen, Deutschland.
C Hegeler-MolkewehrumKardiologisch-Angiologische Praxis, Herzzentrum Bremen, Bremen, Deutschland.
M SudauKlinik für Kardiologie und Diabetologie, Klinikum Magdeburg gGmbH, Magdeburg, Deutschland.
H SchmidtMedizinische Fakultät, Martin Luther-Universität Halle-Wittenberg, Halle-Wittenberg, Deutschland.
Klinikum Magdeburg · DEKlinikum Bremen-Mitte · DEMammazentrum Hamburg · DEParacelsus-Harz-Klinik Bad Suderode · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients with moderate to severe mitral regurgitation cannot be subjected to surgical therapy due to their multimorbidity. For these patients, MitraClip® implantation is a therapeutic alternative.The aim of this article is to present recommendations for treatment after a MitraClip® procedure. For this purpose, a selective literature review has been carried out based on the current literature, notably on national and international guidelines.After a MitraClip® procedure, rehabilitation is indicated because of the underlying heart failure as well as the treatment of a heart valve. Here, optimization of drug therapy, implementation of standardized heart failure training, the initiation of strength and endurance training and psychosocial support are initiated. Patients will be briefed on endocarditis prophylaxis lasting for at least six months. Furthermore, according to current guidelines, treatment with ACE inhibitors, beta-blockers and aldosterone antagonists are optimized. A special feature is anticoagulation, which is currently empirically accounted for and performed in sinus rhythm typically for four weeks of dual antiplatelet therapy (aspirin and clopidogrel) followed by a monotherapy with aspirin. In atrial fibrillation, lifelong oral anticoagulation is indicated combined with a platelet aggregation inhibitor for four weeks.In particular, echocardiographic control in the rehabilitation clinic and by cardiologists has to be focused on a residual atrial septal defect, the transmitral gradient and a residual mitral regurgitation.

Indexed as

AftercareCardiac CatheterizationEndocarditisEvidence-Based MedicineHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansMitral Valve AnnuloplastyMitral Valve InsufficiencyThrombosisTreatment OutcomeHeart FailureHeart Septical Defects, ArterialHeart ValvesMitral Regurgitation

Identifiers

PMID27349588
OpenAlexW2499901186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.